Crinetics Pharmaceuticals, Inc. (CRNX)
84.79
+0.10
(+0.12%)
USD |
NASDAQ |
Aug 24, 16:00
84.79
0.00 (0.00%)
After-Hours: 20:00
Crinetics Pharmaceuticals Enterprise Value : 7.802B for Aug. 21, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 21, 2026 | 7.802B |
| August 20, 2026 | 7.802B |
| August 19, 2026 | 7.802B |
| August 18, 2026 | 7.805B |
| August 17, 2026 | 7.809B |
| August 14, 2026 | 7.803B |
| August 13, 2026 | 7.776B |
| August 12, 2026 | 7.778B |
| August 11, 2026 | 7.767B |
| August 10, 2026 | 7.745B |
| August 07, 2026 | 7.738B |
| August 06, 2026 | 7.721B |
| August 05, 2026 | 7.729B |
| August 04, 2026 | 7.714B |
| August 03, 2026 | 7.704B |
| July 31, 2026 | 7.679B |
| July 30, 2026 | 7.690B |
| July 29, 2026 | 7.717B |
| July 28, 2026 | 7.714B |
| July 27, 2026 | 7.713B |
| July 24, 2026 | 7.701B |
| July 23, 2026 | 7.692B |
| July 22, 2026 | 7.700B |
| July 21, 2026 | 7.719B |
| July 20, 2026 | 7.716B |
| Date | Value |
|---|---|
| July 17, 2026 | 7.714B |
| July 16, 2026 | 7.720B |
| July 15, 2026 | 7.719B |
| July 14, 2026 | 7.699B |
| July 13, 2026 | 7.694B |
| July 10, 2026 | 7.685B |
| July 09, 2026 | 7.689B |
| July 08, 2026 | 7.675B |
| July 07, 2026 | 7.680B |
| July 06, 2026 | 3.289B |
| July 02, 2026 | 3.310B |
| July 01, 2026 | 2.934B |
| June 30, 2026 | 2.801B |
| June 29, 2026 | 2.647B |
| June 26, 2026 | 2.622B |
| June 25, 2026 | 2.441B |
| June 24, 2026 | 2.567B |
| June 23, 2026 | 2.538B |
| June 22, 2026 | 2.483B |
| June 18, 2026 | 2.534B |
| June 17, 2026 | 2.522B |
| June 16, 2026 | 2.443B |
| June 15, 2026 | 2.455B |
| June 12, 2026 | 2.387B |
| June 11, 2026 | 2.288B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Vertex Pharmaceuticals, Inc. | 132.96B |
| Johnson & Johnson | 679.08B |
| Eli Lilly & Co. | 1.228T |
| Pfizer Inc. | 211.77B |
| Bristol Myers Squibb Co. | 170.89B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -120.86M |
| Revenue (Quarterly) | 25.12M |
| Total Expenses (Quarterly) | 145.97M |
| EPS Diluted (Quarterly) | -1.145 |
| Gross Profit Margin (Quarterly) | 95.12% |
| Profit Margin (Quarterly) | -481.1% |
| Earnings Yield | -5.95% |
| Normalized Earnings Yield | -5.950 |